 |
| Emma Lynn |
Edelman has recruited Pfizer UK’s corporate affairs director Emma Lynn as global health deputy.
Lynn, who did a 16-year run at Pfizer, reports to Kirsty Graham, head of the specialized global health offering.
She also put in stints at GSK and Burson-Marsteller.
Edelman Health chalked up a robust performance during the 2020 pandemic year as fee income rose 9.1 percent to $168.8M. The firm is No. 2 behind Real Chemistry, the former W2O Group, on O’Dwyer’s roster of healthcare firms.
Edelman also added Lynda Gordon as executive VP, global DXI Health lead.
Gordon joins from the VP-analytics post at Merkle and reports to Yannis Kotziagkiaouridis, global chief data and analytics officer.
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
